Why PCOS affects fertility
The central fertility consequence of PCOS is anovulation — irregular or absent ovulation. Conception requires a viable egg to be released at ovulation and fertilised within a narrow window. When ovulation is infrequent or unpredictable, this window occurs less often, and the probability of conception per menstrual cycle drops substantially.
PCOS is the most common cause of ovulatory infertility worldwide. In the Indian context, where fertility pressure is often experienced early and intensely, this creates significant emotional and clinical urgency. The important reassurance is that PCOS-related infertility is, in the majority of patients, addressable with established clinical approaches.
What the evaluation covers
Before discussing fertility management, a doctor will typically evaluate:
Confirming the diagnosis. PCOS is a diagnosis of exclusion. Conditions that can mimic PCOS — thyroid dysfunction, hyperprolactinaemia, non-classical congenital adrenal hyperplasia, and androgen-secreting tumours — must be ruled out. A hormonal panel including TSH, prolactin, DHEAS, 17-OH progesterone, and androgens provides this context.
Partner evaluation. Fertility is a couple's concern. A semen analysis should be part of the initial evaluation. Addressing male factor infertility alongside PCOS management avoids the situation where one partner is treated extensively while the limiting factor is on the other side.
Tubal and uterine assessment. PCOS affects ovulation, not tubal function or uterine anatomy. A hysterosalpingogram or other assessment of tubal patency is appropriate when there are risk factors for tubal disease (prior pelvic inflammatory disease, endometriosis, prior abdominal surgery) or when ovulation induction has not resulted in conception after adequate attempts.
Metabolic evaluation. As discussed in the insulin resistance article, PCOS patients with significant insulin resistance may have impaired ovulatory function driven by the metabolic component. Improving insulin sensitivity — through lifestyle change or medication — sometimes restores ovulation independently of other interventions.
Ovulation induction: what the evidence supports
When lifestyle optimisation does not restore ovulation, and after partner evaluation is complete, ovulation induction is the first-line approach.
Letrozole. The landmark 2014 NEJM trial by Legro et al. demonstrated that letrozole — an aromatase inhibitor originally used in breast cancer treatment — outperformed clomiphene (the previous standard) in live birth rates (27.5% vs 19.1% per cycle) in women with PCOS. Letrozole has since become the preferred first-line agent in most guidelines, including those applicable to Indian practice. It is given orally in the early days of the cycle to stimulate follicular development and ovulation.
Clomiphene citrate. An older ovulation induction agent with decades of use. It remains effective, particularly at lower doses, and may be appropriate in certain clinical contexts. It has a higher multiple pregnancy rate than letrozole (due to multi-follicular stimulation) and a cumulative clomiphene resistance that develops in some patients.
Metformin. Insulin sensitisation with metformin, particularly in patients with significant insulin resistance, can restore spontaneous ovulation in some PCOS patients. It is sometimes used as an adjunct to letrozole or clomiphene, and evidence supports its role in reducing miscarriage risk in early pregnancy.
When further intervention is considered
If ovulation induction with letrozole or clomiphene does not result in conception after an adequate number of well-monitored cycles (typically 3–6 cycles), the evaluation moves to the next tier:
Gonadotrophin stimulation. Injectable FSH (follicle-stimulating hormone) stimulates follicular development more potently than oral agents. It requires closer monitoring to avoid overstimulation, and the multiple pregnancy risk is higher. It is typically managed by a fertility specialist.
Laparoscopic ovarian drilling. A surgical procedure in which small punctures are made in the ovarian cortex under laparoscopy. It reduces androgen levels and can restore ovulatory cycles in a proportion of PCOS patients who have not responded to oral ovulation induction. The effect may last one to two years. Its role is decreasing as medical alternatives improve.
In vitro fertilisation. IVF may be considered when simpler approaches have been unsuccessful or when other factors (tubal disease, significant male factor) are present. PCOS patients undergoing IVF have a higher risk of ovarian hyperstimulation syndrome (OHSS) — a potentially serious complication — and require a modified stimulation protocol.
The emotional dimension
For many Indian women, the fertility implications of a PCOS diagnosis carry enormous weight — from personal desire to family and social pressure. The clinical evaluation should proceed in parallel with honest, realistic counselling about what is likely, what is possible, and what timelines look like.
Most women with PCOS who want to conceive will conceive. The pathway may take longer and require more clinical support than an unaffected patient — but it is not, for the majority, closed.